article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

While that sounds encouraging, most cancer drugs launched between 2009 and 2014 cost more than USD 100,000 annually. This leads to a question; “where does it end?” COVID-19 has not impacted the number of launches in the oncology space, as 2020 and 2021 have seen similar rates of drug launches as in 2019.

Pharma 210
article thumbnail

EC approves Novartis’ Tabrecta for non-small cell lung cancer

Pharmaceutical Technology

The treatment is intended for patients with NSCLC harbouring alterations leading to mesenchymal-epithelial-transition factor gene (MET) exon 14 (METex14) skipping and for those who need systemic therapy after previous treatment with immunotherapy and/or platinum-based chemotherapy. It was discovered by Incyte and licensed to Novartis in 2009.

Medicine 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Impact of IFM 2009 and DETERMINATION Studies

Pharmacy Times

Panelists discuss how the introduction of triplet therapy prior to transplant in studies like IFM 2009 and DETERMINATION shifted the clinician mindset toward more intensive induction regimens, leading to a focus on achieving deeper responses and longer progression-free survival as primary goals of therapy for newly diagnosed multiple myeloma patients. (..)

Leads 26
article thumbnail

Common sense approach to the pharma industry

World of DTC Marketing

As the NY Times reported , obesity is the leading cause of mortality in the United States. healthcare system saved almost $2 trillion from 2009 to 2019 in healthcare costs due to generic drugs. When a new drug is on the horizon stories, the effect, the drug will have on its stock price, not on patients. Obesity costs the nation $1.72

Pharma 155
article thumbnail

Innovative Medicines Fund and the opportunity for ICSs to mobilise NICE approvals

pharmaphorum

Nina Pinwill leads the commercial operations function within the Commercial Medicines Directorate at NHS England. Alongside his work as a recognised author, speaker, moderator and industry advisor, he founded the industry-leading publication pharmaphorum in 2009. She is an SME in market access, rare disease and biosimilars.

Medicine 122
article thumbnail

Qualitative Benefits of Strategic Planning

Medical Device Success

BUT, you are beginning to wonder if good planning may lead to increased revenues, more targeted marketing, enhanced sales activity, etc. Perhaps your company is struggling in the wake of the 2009 economic downturn. so after the last post you are thinking about strategic planning but may not be convinced. You have a lot on your plate.

article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

Over the last 25 years, the headcount in the medicines manufacturing sector has fallen by 7,000 and since 2009 production volumes have fallen by nearly a third (29%), suggesting “faltering attractiveness” of the UK for manufacturing. Established trends are unfortunately firmly in the wrong direction.